<a href="https://laohu8.com/S/NAOV">NanoVibronix Inc</a>. Announces Debt Repayment and Preferred Share Conversion Plan Following $10 Million Public Offering
NanoVibronix, Inc., a medical technology company, has announced the pricing of a $10 million public offering involving Series G Convertible Preferred Stock and Warrants. The offering includes approximately 400,000 shares of Preferred Stock and Warrants to purchase up to 4,901,961 shares of common stock. The proceeds from this offering are intended to be used for the redemption of the principal amount of an outstanding debenture and a partial repayment of an outstanding note, alongside general corporate purposes. The transaction is expected to close around May 19, 2025, contingent upon customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoVibronix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-011246), on May 16, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。